The current leaflet provided with another brand of the drug, made by Wockhardt, clearly highlights risks to any unborn child including spina bifida, congenital abnormalities and delayed development.
Judge Cavanaugh said Wockhardt had failed to show that Sepracor knew the information was false, and that patent examiners had the data in front of them and could have drawn their own conclusions.